IRIS
Valenti, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.845
AS - Asia 2.277
EU - Europa 565
SA - Sud America 526
Continente sconosciuto - Info sul continente non disponibili 114
AF - Africa 67
OC - Oceania 4
Totale 6.398
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.734
SG - Singapore 1.320
CN - Cina 478
BR - Brasile 412
VN - Vietnam 236
IT - Italia 179
HK - Hong Kong 65
GB - Regno Unito 52
FR - Francia 51
AR - Argentina 49
CA - Canada 49
IE - Irlanda 49
FI - Finlandia 45
IN - India 43
DE - Germania 39
MX - Messico 31
EC - Ecuador 29
BD - Bangladesh 24
NG - Nigeria 19
NL - Olanda 19
RU - Federazione Russa 19
ZA - Sudafrica 16
BE - Belgio 15
SE - Svezia 14
ES - Italia 13
IQ - Iraq 13
JP - Giappone 13
ID - Indonesia 12
PL - Polonia 12
PK - Pakistan 11
UA - Ucraina 11
TR - Turchia 10
VE - Venezuela 9
CO - Colombia 7
GR - Grecia 7
PE - Perù 7
TN - Tunisia 7
DZ - Algeria 6
MY - Malesia 6
NP - Nepal 6
AT - Austria 5
UZ - Uzbekistan 5
AU - Australia 4
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
MA - Marocco 4
NI - Nicaragua 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
AG - Antigua e Barbuda 3
DO - Repubblica Dominicana 3
EG - Egitto 3
HN - Honduras 3
KR - Corea 3
KZ - Kazakistan 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
SA - Arabia Saudita 3
SN - Senegal 3
SR - Suriname 3
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
EE - Estonia 2
ET - Etiopia 2
KW - Kuwait 2
LB - Libano 2
MT - Malta 2
OM - Oman 2
PY - Paraguay 2
QA - Qatar 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
GE - Georgia 1
GT - Guatemala 1
HT - Haiti 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
PS - Palestinian Territory 1
RS - Serbia 1
SV - El Salvador 1
Totale 6.283
Salva come PNG Salva come JPEG
Città #
Singapore 488
San Jose 364
Ashburn 284
Shanghai 168
Beijing 159
Chandler 150
The Dalles 144
Council Bluffs 133
Dallas 124
Ho Chi Minh City 100
Santa Clara 88
Boardman 80
New York 74
Los Angeles 71
Milan 65
Hong Kong 63
Dublin 49
Helsinki 45
Hanoi 38
São Paulo 32
Phoenix 29
Wilmington 25
Rome 24
Princeton 23
San Mateo 23
Lawrence 22
North Bergen 21
Benin City 19
Brooklyn 19
Buffalo 19
Paris 18
Orem 15
Chicago 14
Atlanta 13
Brussels 13
Guayaquil 13
Amsterdam 12
Rio de Janeiro 12
Seattle 12
Mexico City 11
Montreal 11
Tokyo 11
London 10
Ann Arbor 9
Chennai 9
Da Nang 9
Johannesburg 9
Queens 9
Assago 8
Boston 8
Charlotte 8
Belo Horizonte 7
Detroit 7
Duncan 7
Figino 7
Haiphong 7
Las Vegas 7
Mogi das Cruzes 7
Munich 7
Poplar 7
Salvador 7
Toronto 7
Baghdad 6
Buenos Aires 6
Can Tho 6
Columbus 6
Curitiba 6
Frankfurt am Main 6
Houston 6
Lima 6
Minneapolis 6
Moscow 6
Quito 6
San Francisco 6
The Bronx 6
Warsaw 6
Washington 6
Brasília 5
Cleveland 5
Dhaka 5
Falkenstein 5
Hangzhou 5
Hải Dương 5
Madrid 5
New Delhi 5
Pasadena 5
Philadelphia 5
Raleigh 5
San Antonio 5
San Diego 5
Uberlândia 5
Amman 4
Bergamo 4
Biên Hòa 4
Bratislava 4
Brno 4
Brownsville 4
Calgary 4
Caracas 4
Caraguatatuba 4
Totale 3.450
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 213
Brodalumab: a new way to inhibit IL-17 in psoriasis 133
Chronic Hand Eczema (CHE): A Narrative Review 129
Rosacea-like Acute Reaction After Hyaluronic Acid Dermal Filler 119
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 117
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 104
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 102
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 101
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 94
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 93
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 92
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 92
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 85
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 81
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 79
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 78
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 78
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 75
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 74
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 74
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 74
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 74
Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021 73
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 72
Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options 72
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 71
Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers 71
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 69
Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study 69
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 69
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 69
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 68
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 68
Real-life efficacy of guselkumab in patients with early psoriatic arthritis 66
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 65
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 64
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real‐life Italian multicenter observational study of 250 patients 63
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 61
Bullous vasculitis associated with Streptococcus pyogenes sepsis 60
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma 60
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 60
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 59
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 59
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 58
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 58
Urticarial rash in autoinflammatory syndromes 58
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 57
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 57
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 56
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 56
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 56
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 56
Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials 56
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 55
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 55
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 54
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 54
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 53
Multiple facial angiofibromas: A manifestation of Frank-ter Haar syndrome? 53
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion 52
An updated safety review of Hidradenitis Suppurativa treatment options 52
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 52
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 51
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience 51
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 51
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 50
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel 50
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis) 50
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 49
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 49
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 49
Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case‐series 48
Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study 48
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 48
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review 47
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 47
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 47
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 47
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report 47
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 46
A severe case of IgA bullous pemphigoid successfully treated with dupilumab 46
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study 45
Methotrexate-Induced Mucositis in a Patient With Angioimmunoblastic T-cell Lymphoma 45
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) 44
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 44
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 44
Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features 44
Long-Term Sequential Digital Dermoscopy of Low-Risk Patients May Not Improve Early Diagnosis of Melanoma Compared to Periodical Handheld Dermoscopy 43
Long-term management of pediatric psoriasis with ixekizumab: a case report 43
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients 42
Connective tissue panniculitis and vitiligo in a patient with stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy 40
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management 39
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience 38
Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation 38
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study 38
Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers 36
Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals 33
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 32
Age-Related Variations in Clinical, Histological, and Genetic Characteristics in Multiple and Familial Melanomas: A Study of 333 Patients 26
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series 26
Totale 6.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.036
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022106 0 0 0 13 2 3 5 10 26 8 32 7
2022/2023359 55 28 25 58 33 27 0 29 55 29 20 0
2023/2024528 16 37 98 28 11 49 59 45 12 22 52 99
2024/20251.163 13 35 14 19 5 105 87 61 161 222 216 225
2025/20263.086 440 242 217 285 183 142 748 168 140 194 148 179
2026/20271.096 216 212 508 160 0 0 0 0 0 0 0 0
Totale 6.398